ArticleDiscover oncology2026
Cutaneous metastases from intrahepatic cholangiocarcinoma: a case report.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCutaneous metastases from primary malignant neoplasms are rare in clinical practice, especially in intrahepatic cholangiocarcinoma(ICC). ICC features highly invasive and metastatic biological behaviors, early extrahepatic metastasis. Distant lymph nodes are the most common metastatic site for ICC, followed by the lungs and bones, whereas Cutaneous metastasis is very rare, usually indicating a poor prognosis and low survival rate. CASE PRESENTATION: We present the case of a 69-year-old woman with cutaneous metastases from ICC who survived for four years. The patient underwent cutaneous metastatic tumor resection, chemotherapy, targeted therapy, and immune checkpoint inhibitors combined treatment, achieving long-term disease control. In this case, multidisciplinary treatment can delay the progression of the disease to a certain extent and improve the quality of life for the patient.
conclusionCutaneous metastases from intrahepatic cholangiocarcinoma are exceedingly rare and therapeutic challenges. While treatment protocols lack standardization, combination therapy of surgical resection with ICI and targeted therapy shows promising efficacy in cutaneous metastases from ICC. Continued research and collaboration are essential to further refine therapeutic strategies, ultimately enhancing outcomes for patients with cutaneous metastases from ICC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.